↓ Skip to main content

Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature

Overview of attention for article published in BMC Cancer, April 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter
13 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
21 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
Published in
BMC Cancer, April 2022
DOI 10.1186/s12885-022-09475-7
Pubmed ID
Authors

Laura Caquelin, Mohamed Gewily, Wendy Mottais, Chloé Tebaldi, Bruno Laviolle, Florian Naudet, Clara Locher

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 10%
Other 1 5%
Professor 1 5%
Student > Bachelor 1 5%
Student > Master 1 5%
Other 1 5%
Unknown 14 67%
Readers by discipline Count As %
Nursing and Health Professions 2 10%
Business, Management and Accounting 1 5%
Computer Science 1 5%
Social Sciences 1 5%
Medicine and Dentistry 1 5%
Other 1 5%
Unknown 14 67%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 June 2023.
All research outputs
#5,048,130
of 24,907,378 outputs
Outputs from BMC Cancer
#1,287
of 8,817 outputs
Outputs of similar age
#107,988
of 436,112 outputs
Outputs of similar age from BMC Cancer
#30
of 288 outputs
Altmetric has tracked 24,907,378 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,817 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,112 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 288 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.